Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
Revolution Medicines in San Francisco is seeking an Associate Director in Clinical Biomarker Development. This role involves designing and executing clinical biomarker strategies for oncology pipelines, from phase 1 through phase 3 studies.
The ideal candidate will hold a Ph.D. and have at least 3 years of experience in clinical biomarker development. A hybrid work arrangement is offered, with offices in Redwood City, CA, providing flexibility for remote work.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC‑6236), elironrasib (RMC‑6291), zoldonrasib (RMC‑9805), and RMC‑5127 are currently in clinical development.
The Associate Director in the Clinical Biomarker Development team, within Translational Medicine, will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicines’ oncology pipeline.
Hybrid – offices in Redwood City, CA with flexibility for remote work.
$186,000 – $233,000 USD
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.